Premium
Vasopressin Antagonists for Patients With Acute Heart Failure: Interpreting New Clinical and Translational Data
Author(s) -
Feldman A M,
Hamad E,
Tsai E J,
Zhu W,
Tilley D G,
Alvarez R,
Cheung J Y
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.240
Subject(s) - vasopressin , hyponatremia , medicine , heart failure , arginine , vasopressin antagonists , arginine vasopressin receptor 2 , vasopressin receptor , endocrinology , intensive care medicine , cardiology , pharmacology , receptor , antagonist , amino acid , chemistry , biochemistry
Elevated levels of arginine vasopressin (AVP) are associated with a worse prognosis and the development of hyponatremia in patients with heart failure (HF). This observation led to the development of AVP receptor antagonists for the treatment of HF patients. Although AVP receptor antagonists increase serum sodium, their overall benefits in patients with HF have been at best modest, and recent data raise concerns about their safety in patients with acute HF and low serum sodium.